"We are executing our plan and are now in full launch mode with Cambia®" said Rob Harris, CEO of Tribute. "We believe Cambia® has the potential to gain a significant proportion of the $150 million Canadian migraine market. We believe it is the only available prescription non-steroidal anti-inflammatory drug ("NSAID") available with an indication for the acute treatment of migraine attacks with or without aura in adults in Canada." Mr. Harris went on to state, "We are pleased with our results for Q1-2013. Our promoted products including Bezalip SR and Soriatane continue to show good growth in Canada. We are pleased with our business development efforts and feel confident in our ability to bring new products to Canada. Furthermore, we are making good progress on the preparation of the Bezalip SR IND in the US and are still on track to file this with the FDA before the end of the year."
About Tribute Pharmaceuticals Canada Inc.
Tribute is an emerging Canadian specialty pharmaceutical company focused on the acquisition, licensing, development and management of pharmaceutical and healthcare products with its primary focus on the Canadian market.
Tribute markets Cambia® (diclofenac potassium for oral solution), Bezalip® SR (bezafibrate), Soriatane® (acitretin), NeoVisc® (1.0% sodium hyaluronate solution) Uracyst® (sodium chondroitin sulfate solution 2%), Collatamp G® and Gelfoam® in the Canadian market. Additionally, NeoVisc® and Uracyst® are commercially available and are sold globally through various international partnerships.
For further information on Tribute visit the Company's website: www.tributepharma.com.
Tribute Pharmaceuticals' Forward-Looking Statement
This press release contains certain forward-looking statements about Tribute as defined in the Private Securities Litigation Reform Act of 1995, which statements can be identified by the use of forward-looking terminology, such as "may", "will", "expect", "intend", "anticipate", "estimate", "predict", "plan" or "continue" or the negative thereof or other variations thereon or comparable terminology referring to future events or results. Forward-looking statements, by their nature, are subject to risks and uncertainties, Tribute's actual results could differ materially from those anticipated in these forward-looking statements as a result of numerous factors, including general economic conditions, the ability of Tribute to successfully integrate operations, and the timing of expenditures and expansion opportunities, any of which could cause actual results to vary materially from current results or anticipated future results. See Tribute's reports filed with the Canadian securities regulatory authorities and the U.S. Securities and Exchange Commission from time to time for cautionary statements identifying important factors with respect to such forward-looking statements, including certain risks and uncertainties that could cause actual results to differ materially from results referred to in forward-looking statements. Tribute assumes no obligation to update the information contained in this press release to update forward-looking statements to reflect changed assumptions, the occurrence of anticipated events or changes in future operating results, financial condition or business over time.
Soriatane and Bezalip are registered trademarks and under license from Actavis Group PTC ehf
Most Popular Stories
- Stolen Cobalt-60 Recovered in Mexico
- Hezbollah Chief's Assassination Claimed by Sunni Group
- Sarmiento to Handle Greeley Latin Ops
- Allstate Seeks to Invest in Minority Firms
- First-time Jobless Claims Drop Below 300,000
- SpaceX's Satellite Launch Is 'Game-Changer'
- White House Pushes to Extend Unemployment Benefits
- Wind Power and Wildlife Can Coexist
- Latin Music Conference Turns 25
- Calif. Likes Christie, Says Tea Party's a Drag